PMC6370159_01
Values of tumor markers and chemotherapy regimens from 2013 to 2016.
medi-98-e14020-g001.jpg
PMC6370159_01_medi-98-e14020-g001.jpg
F1
CA125, CA242, and CA19-9 increased repeatedly (Fig. 1). Considering the resistance to chemotherapy, she underwent a pathology consultation at Fudan University Shanghai Cancer Center, resulting in presentation of a high-grade adenocarcinoma, tending toward OCCC.
The images of PET/CT: There is a metabolic anomaly in the right cerebellar hemisphere. PET/CT = positron emission tomography/computed tomography.
medi-98-e14020-g002.jpg
PMC6370159_01_medi-98-e14020-g002.jpg
F2
The patient had a headache, and a positron emission tomography/computed tomography (PET/CT) examination detected a brain mass on 17 May 2016 (Fig. 2).
The images of MRI: In the right cerebellar hemisphere, a mass about 4.5*3.7 cm was seen with a slightly longer T1 and slightly longer T2 signal.
medi-98-e14020-g003.jpg
PMC6370159_01_medi-98-e14020-g003.jpg
F3
Head magnetic resonance imaging (MRI) revealed a mass of about 4.5 x 3.7 cm in the right cerebellar hemisphere (Fig. 3).
The pathological results of brain BM (HE + IHC): clear cell, CK-Pan (+), PAX-8 (+).
medi-98-e14020-g004.jpg
PMC6370159_01_medi-98-e14020-g004.jpg
F4
Immunohistochemistry (IHC) showed EMA (+), CK7 (+), WT1 (-), Calretinin (-), PAX8 (+), P53 (+), P40 (-), Arg-1 (-), AFP (-), HNF1beta(+), and ER (-) (Fig. 4). The postoperative pathological examination revealed a low-differentiation metastatic carcinoma in the cerebellum considered to be OCCC, with IHC findings of GATA3 (+), P53 (+), PR (-), ER (-), P40 (-), CDX-2 (-), CK-Pan (+), and PAX8 (+) (Fig. 4).